Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author:

Spyridonidis AlexandrosORCID,Labopin MyriamORCID,Gedde-Dahl Tobias,Ganser Arnold,Stelljes Matthias,Craddock CharlesORCID,Wagner-Drouet Eva MariaORCID,Versluis JurjenORCID,Schroeder Thomas,Blau Igor Wolfgang,Wulf Gerald. G.,Dreger PeterORCID,Olesen Gitte,Sengeloev Henrik,Kröger NicolausORCID,Potter Victoria,Forcade EdouardORCID,Passweg JakobORCID,de Latour Régis Peffault,Maertens JohanORCID,Wilson Keith M. O.,Bourhis Jean Henri,Finke JuergenORCID,Brissot Eolia,Bazarbachi AliORCID,Giebel Sebastian,Savani Bipin P.ORCID,Nagler ArnonORCID,Ciceri FabioORCID,Mohty MohamadORCID

Abstract

AbstractThe intensity of the conditioning regimen given before allogeneic hematopoietic cell transplantation (allo-HCT) can vary substantially. To confirm the ability of the recently developed transplant conditioning intensity (TCI) score to stratify the preparative regimens of allo-HCT, we used an independent and contemporary patient cohort of 4060 transplant recipients with acute myeloid leukemia meeting inclusion criteria from the discovery study (allo-HCT in first complete remission, matched donor), but who were allografted in a more recent period (2018–2021) and were one decade older (55–75 years, median 63.4 years), we assigned them to a TCI category (low n = 1934, 48%; intermediate n = 1948, 48%, high n = 178, 4%) according to the calculated TCI score ([1–2], [2.5–3.5], [4–6], respectively), and examined the validity of the TCI category in predicting early non-relapse mortality (NRM), 2-year NRM and relapse (REL). In the unadjusted comparison, the TCI index provided a significant risk stratification for d100 and d180 NRM, NRM and REL risk. In the multivariate analysis adjusted for significant variables, there was an independent association of TCI with early NRM, NRM and REL. In summary, we confirm in contemporary treated patients that TCI reflects the conditioning regimen related morbidity and anti-leukemic efficacy satisfactorily and across other established prognostic factors.

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3